Skip to main content

Table 4 Postoperative pathology of the modified invaginated anastomosis and mucosa-to-mucosa anastomosis groups

From: Clinical evaluation of modified invaginated pancreaticojejunostomy for pancreaticoduodenectomy

Pathological type Modified invaginated anastomosis Mucosa-to-mucosa anastomosis P value
Duodenal tumor [number (%)] 71 (35.7%) 38 (26.4%) 0.002
Duodenal papillary adenocarcinoma (number) 38 21  
Duodenal ampullary adenocarcinoma (number) 15 9  
Duodenal adenoma (number) 14 6  
Duodenal neuroendocrine tumor (number) 4 2  
Pancreatic tumor [number (%)] 56 (28.1%) 47 (32.6%) 0.007
Pancreatic ductal adenocarcinoma (number) 32 26  
Pancreatic serous cystadenoma (number) 9 7  
Intraductal papillary mucinous neoplasm (number) 5 6  
Solid pseudopapillary tumor (number) 5 4  
Pancreatic neuroendocrine tumor (number) 4 4  
Pancreatic intraepithelial neoplasia (number) 1 0  
Lower bile duct tumor, [number (%)] 66 (33.2%) 49 (34.0%) 0.113
Bile duct adenocarcinoma (number) 62 44  
Bile duct adenoma (number) 4 5  
Inflammatory lesion (number) 6 (3.0%) 10 (7.0%) 0.317
Chronic pancreatitis (number) 5 8  
Bile duct inflammation (number) 1 2